RxDoctor Payments Data

Miles Murphy, MD

Urogynecology and Reconstructive Pelvic Surgery · Allentown, PANPI 1699701623

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (53.5%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 79.3% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $37,384 and has fallen 91.0% since, to $3,371 in 2025. Among urogynecology and reconstructive pelvic surgery clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$53,802in general payments, 2019–2025

Across 417 payments — averaging $129.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$43K
  • Coloplast$2K
  • Astellas Pharma US Inc$2K
  • AbbVie$1K
  • Medtronic$1K
  • Axonics, Inc.$961
  • plus $4K from 23 others
$147,301in research payments, 2019–2025

Across 116 payments — averaging $1269.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Johnson & Johnson$134K
  • Provepharm Inc.$13K
  • Coloplast$749

What the payments were for

  • Consulting fees$28,80454%
  • Speaking & faculty fees$7,90015%
  • Travel & lodging$7,00213%
  • Food & beverage$8,96217%
  • Education$8672%
  • Gifts$1330%
  • Entertainment$1360%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$53,802 in reported general payments places this provider in the 95th percentile of 51 urogynecology and reconstructive pelvic surgery providers in Pennsylvania.

See all urogynecology and reconstructive pelvic surgery providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$255,542
Medicare patients
349
Services billed
1,819

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron275$185,717
GemtesaVibegron109$81,876
ElmironPentosan Polysulfate Sodium16$15,717
PremarinEstrogens, Conjugated27$11,519
Methenamine Hippurate99$9,235
Estradiol113$6,636
Trospium Chloride ErTrospium Chloride35$5,875
Solifenacin Succinate186$5,067
Fesoterodine Fumarate ErFesoterodine Fumarate19$2,510
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst230$2,217
Tolterodine Tartrate ErTolterodine Tartrate12$2,000
Trospium Chloride35$1,173
Clobetasol Propionate23$721
Oxybutynin Chloride ErOxybutynin Chloride39$533
Amitriptyline Hcl39$350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$1,625$185,717275 claims
Sumitomo Pharma America, Inc.Gemtesa$349$81,876109 claims
PfizerPremarin$398$11,51927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 51 urogynecology and reconstructive pelvic surgery providers in Pennsylvania.

Other urogynecology and reconstructive pelvic surgery in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →